论文部分内容阅读
目的评价抗核小体抗体(AnuA)、抗Sm抗体、抗dsDNA抗体在系统性红斑狼疮诊断中的临床价值。方法采用ELISA法对46例AnuA阳性SLE患者、20例健康体检者的血清进行自身抗体谱联合检测。结果 46例AnuA阳性的SLE患者血清AnuA、抗sm抗体、抗ds-DNA抗体阳性率分别为100.0%、80.4%、47.8%,其中AnuA的阳性率与其他两种自身抗体相比差异有统计学意义(P<0.05)。结论抗核小体抗体(AnnA)是诊断SLE新的指标。
Objective To evaluate the clinical value of anti-nucleosome antibodies (AnuA), anti-Sm antibodies and anti-dsDNA antibodies in the diagnosis of systemic lupus erythematosus. Methods Serum samples of 46 patients with AnuA-positive SLE and 20 healthy controls were detected by ELISA. Results The positive rates of AnuA, anti-sm antibody and anti-dsDNA antibody in 46 AnuA-positive SLE patients were 100.0%, 80.4% and 47.8%, respectively. The positive rate of AnuA was statistically different from the other two autoantibodies Significance (P <0.05). Conclusion Anti-nucleosome antibody (AnnA) is a new diagnostic indicator of SLE.